Vertex price target raised to $60 from $57 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...
Seeking Alpha1d
VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
Yahoo Finance4d
Vertex Pharmaceuticals Incorporated (VRTX)
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.
pharmaphorum2d
Vertex buys diabetes cell therapy rival ViaCyte for $320m
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
Yahoo Finance4d
Vertex Pharmaceuticals Incorporated (VRTX)
After hours: March 21 at 7:13:50 PM EDT Loading Chart for VRTX ...